JP2021512921A - 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン - Google Patents

癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン Download PDF

Info

Publication number
JP2021512921A
JP2021512921A JP2020542862A JP2020542862A JP2021512921A JP 2021512921 A JP2021512921 A JP 2021512921A JP 2020542862 A JP2020542862 A JP 2020542862A JP 2020542862 A JP2020542862 A JP 2020542862A JP 2021512921 A JP2021512921 A JP 2021512921A
Authority
JP
Japan
Prior art keywords
ibudilast
administered
pharmaceutically acceptable
acceptable salt
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542862A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019157423A5 (https=
JP2021512921A5 (https=
Inventor
和子 松田
和子 松田
マクドナルド，ケリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2021512921A publication Critical patent/JP2021512921A/ja
Publication of JPWO2019157423A5 publication Critical patent/JPWO2019157423A5/ja
Publication of JP2021512921A5 publication Critical patent/JP2021512921A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020542862A 2018-02-12 2019-02-11 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン Pending JP2021512921A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629579P 2018-02-12 2018-02-12
US62/629,579 2018-02-12
PCT/US2019/017430 WO2019157423A1 (en) 2018-02-12 2019-02-11 Methods and dosing regimens using ibudilast and a second agent for cancer therapy

Publications (3)

Publication Number Publication Date
JP2021512921A true JP2021512921A (ja) 2021-05-20
JPWO2019157423A5 JPWO2019157423A5 (https=) 2022-02-17
JP2021512921A5 JP2021512921A5 (https=) 2022-02-17

Family

ID=67542181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542862A Pending JP2021512921A (ja) 2018-02-12 2019-02-11 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン

Country Status (6)

Country Link
US (2) US10744123B2 (https=)
EP (1) EP3752147A4 (https=)
JP (1) JP2021512921A (https=)
CN (1) CN112236140A (https=)
CA (1) CA3090884A1 (https=)
WO (1) WO2019157423A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019157423A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
CN113584172B (zh) * 2021-08-04 2022-08-02 中南大学湘雅二医院 Slc12a5及其抑制剂的应用
US20230090534A1 (en) * 2021-09-21 2023-03-23 Medicinova, Inc. Methods of treating glioblastoma multiforme using combination therapy
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540455A (ja) * 2005-05-05 2008-11-20 コンビナトアールエックス インコーポレーティッド 新生物治療のための組成物および方法
JP2015511936A (ja) * 2012-01-20 2015-04-23 ブラウン、デニス 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1106178T3 (da) 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20160361298A1 (en) * 2015-06-11 2016-12-15 Globavir Biosciences, Inc. Methods and compositions for treating cancer
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
WO2019157423A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540455A (ja) * 2005-05-05 2008-11-20 コンビナトアールエックス インコーポレーティッド 新生物治療のための組成物および方法
JP2015511936A (ja) * 2012-01-20 2015-04-23 ブラウン、デニス 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol. 25 Issue 22, JPN6022050059, 2007, pages 3357 - 3361, ISSN: 0005091999 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol. 35, Issue 15, Suppl. 2062, JPN6022050057, 2017, ISSN: 0005091998 *

Also Published As

Publication number Publication date
WO2019157423A1 (en) 2019-08-15
CN112236140A (zh) 2021-01-15
CA3090884A1 (en) 2019-08-15
US10744123B2 (en) 2020-08-18
US20190247370A1 (en) 2019-08-15
US20210023063A1 (en) 2021-01-28
EP3752147A1 (en) 2020-12-23
EP3752147A4 (en) 2021-10-20
US11446283B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
EP2187882B1 (en) Treatment of progressive neurodegenerative disease with ibudilast
US10391085B2 (en) Methods of treating glioblastoma multiforme using ibudilast
JP5411504B2 (ja) 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用
US11446283B2 (en) Methods and dosing regimens using ibudilast and a second agent for cancer therapy
US20080114027A1 (en) Method for treating delirium
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
ES2959799T3 (es) Métodos para suprimir células supresoras de origen mieloide en pacientes
US12005049B2 (en) Methods of preventing cancer metastasis
ES2973119T3 (es) Combinación de ibudilast e interferón-beta y métodos de uso
ES2970996T3 (es) Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
WO2017106584A1 (en) Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230627